DCLK1 and cancer: Previous studies with non-specific DCLK1 kinase inhibitors LRRK2-IN-1 and XMD8-92 demonstrated downregulation of DCLK1’s protein expression [16,19], complicating interpretation since the downregulation or knockout of DCLK1 inhibits cancer functional properties including proliferation, invasion, stemness, and angiogenesis [14,20,21].